2017
DOI: 10.1021/acsmedchemlett.7b00397
|View full text |Cite
|
Sign up to set email alerts
|

Correction to “Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors”

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
0
0

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
0
0
Order By: Relevance
“…45 Researchers from AstraZeneca and X-Chem reported the identification of an Mcl-1 inhibitor, which was further optimized to a macrocyclic compound based on ligand-protein crystal structures and binding kinetics (Figure1-10, 15-16). 166 Researchers from BMS and Ensemble Therapeutics identified XIAP BIR2 and BIR3 domain inhibitors after screening of macrocycle libraries synthesized by DNA-programmed chemistry. A subsequent bivalent macrocycle library was generated based on the initial screening results and structure based drug design from which the most potent compound was identified.…”
Section: Hit Identificationmentioning
confidence: 99%
See 1 more Smart Citation
“…45 Researchers from AstraZeneca and X-Chem reported the identification of an Mcl-1 inhibitor, which was further optimized to a macrocyclic compound based on ligand-protein crystal structures and binding kinetics (Figure1-10, 15-16). 166 Researchers from BMS and Ensemble Therapeutics identified XIAP BIR2 and BIR3 domain inhibitors after screening of macrocycle libraries synthesized by DNA-programmed chemistry. A subsequent bivalent macrocycle library was generated based on the initial screening results and structure based drug design from which the most potent compound was identified.…”
Section: Hit Identificationmentioning
confidence: 99%
“…The original hit was identified from a DNA-encoded linear peptide library; then structure based drug design led to macrocyclization, which showed a 10-fold binding potency improvement over its linear version. 166 3. In traditional small molecule organic synthesis, macrocyclizations usually run in very diluted concentration (sub-mM to mM) to avoid dimer-or polymerization, which is considered a big hurdle of varies macrocyclization reactions.…”
Section: Macrocycles In Drug Discoverymentioning
confidence: 99%